Abstract
Background: Transcriptome analyses have revealed the presence of numerous long non-coding RNAs (lncRNAs) in mammalian cells. Many lncRNAs are expressed in development-, differentiation-, and disease-specific manners, suggesting their importance as cell regulators. Some nuclear lncRNAs are bound to specific genomic loci, either near or distant from their own transcription sites, and regulate gene expression in cis or trans. These lncRNAs recruit epigenetic factors, including the DNA methyl transferase and histone modification complex, and mediate both the 3D genome structure and nuclear domains. LncRNAs are now considered as an emerging member of epigenetic regulators. LncRNAs are dysregulated in various types of cancer and act as either oncogenic or tumor- suppressing factors. They are involved in virtually all of the cancer hallmarks and are potential diagnostic markers and therapeutic targets.
Objective: In this review, we describe several representative lncRNAs and provide a current overview of the mechanisms by which lncRNAs participate in epigenetic regulation and contribute to cancer development.
Keywords: Long non-coding RNA, epigenetics, cancer, histone modification, DNA methylation, ELEANORS, chromatin.
Current Medicinal Chemistry
Title:Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Volume: 28 Issue: 25
Author(s): Hiroaki Tachiwana and Noriko Saitoh*
Affiliation:
- Division of Cancer Biology, The Cancer Institute of JFCR, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550,Japan
Keywords: Long non-coding RNA, epigenetics, cancer, histone modification, DNA methylation, ELEANORS, chromatin.
Abstract:
Background: Transcriptome analyses have revealed the presence of numerous long non-coding RNAs (lncRNAs) in mammalian cells. Many lncRNAs are expressed in development-, differentiation-, and disease-specific manners, suggesting their importance as cell regulators. Some nuclear lncRNAs are bound to specific genomic loci, either near or distant from their own transcription sites, and regulate gene expression in cis or trans. These lncRNAs recruit epigenetic factors, including the DNA methyl transferase and histone modification complex, and mediate both the 3D genome structure and nuclear domains. LncRNAs are now considered as an emerging member of epigenetic regulators. LncRNAs are dysregulated in various types of cancer and act as either oncogenic or tumor- suppressing factors. They are involved in virtually all of the cancer hallmarks and are potential diagnostic markers and therapeutic targets.
Objective: In this review, we describe several representative lncRNAs and provide a current overview of the mechanisms by which lncRNAs participate in epigenetic regulation and contribute to cancer development.
Export Options
About this article
Cite this article as:
Tachiwana Hiroaki and Saitoh Noriko *, Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer, Current Medicinal Chemistry 2021; 28 (25) . https://dx.doi.org/10.2174/0929867328666210215114506
DOI https://dx.doi.org/10.2174/0929867328666210215114506 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ER Stress and Autophagy
Current Molecular Medicine Preclinical Models to Study Breast Cancer
Clinical Cancer Drugs Cancer and Stem Cells
Current Cancer Therapy Reviews Multidimensional Ophthalmic Nanosystems for Molecular Detection and Therapy of Eye Disorders
Current Pharmaceutical Design Post-translational and Post-transcriptional Modifications of Pregnane X Receptor (PXR) in Regulation of the Cytochrome P450 Superfamily
Current Drug Metabolism The Interplay between Cofilin and Phospho-Cofilin: Its Role in Maintaining Blood Brain Barrier Integrity
CNS & Neurological Disorders - Drug Targets Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Drug Transporters in Chemotherapy Induced Peripheral Neurotoxicity:Current Knowledge and Clinical Implications
Current Medicinal Chemistry Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics
Current Drug Metabolism Patent Selections
Recent Patents on Biotechnology Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy CFTR Gene Transfer to Lung Epithelium - On the Trail of a Target Cell
Current Gene Therapy Non-Analgesic Effects of Opioids: Peripheral Opioid Receptors as Promising Targets for Future Anti-Pruritic Therapies
Current Pharmaceutical Design The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) HPV Vaccination in Adolescents: From Clinical Data to Implementation and Practice
Current Cancer Therapy Reviews Epithelial-Mesenchymal Transitions and Cancer
Current Genomics Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Current Pharmaceutical Design KSP Inhibitors as Antimitotic Agents
Current Topics in Medicinal Chemistry Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics
Current Respiratory Medicine Reviews